Premium
Wet AMD treatment with ranibizumab ‐ structural and functional changes during treatment
Author(s) -
RADECKA L,
LAGANOVSKA G
Publication year - 2009
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2009.420.x
Subject(s) - medicine , ranibizumab , visual acuity , ophthalmology , retinal , macular degeneration , optical coherence tomography , surgery , bevacizumab , chemotherapy
Purpose To analyse the changes of central retinal thickness and visual acuity in patients with subfoveolar neovascular membrane due to wet age‐related macular degeneration who have been treated with intravitreal ranibizumab 0,5mg injections. Methods Ten patients with wet AMD received monthly treatment with ranibizumab (Lucentis). All patients have recieved three or more injections up till now. Measurement of central retinal thickness was done by using optical coherence tomography (OCT). All injections were done in P.Stradins University Clinical Hospital, Riga during October 2008 ‐ May 2009. Results Eight female and two male patients with active subfoveolar neovascular membrane were observed. Age of patients was from 62 up to 84 years (mean age 75 years). Mean central reinal thickness before treatment was 395 ±166μm and visual acuity 0.3 ±0,17. A month after the first injection mean central retinal thickness was 283±56μm (mean improvement by 111,5μm) and visual acuity 0,34±0,2. Mean central retinal thickness after the third injection of ranibizuamab was 222,4±62μm (reduction by 172,7μm compared with baseline findings) and visual acuity was 0,37±0,28 (mean improvement by 0,05 ( in one case even by 0,3)). Conclusion Our results of intravitreal injection of ranibizumab show improvement or stabilisation of visual acuity and reduction of central retinal thickness in all cases. The major improvement in most cases we observe after the first injection and stabilisation after following injections.